HIV
Our nanoDDI platform is designed to deliver long-acting HIV prevention without the daily pill
Powering consistency in HIV prevention
The nanoDDI is a subcutaneous nanofluidic implant designed to deliver PrEP therapy continuously over extended periods without daily dosing.
Placed beneath the skin in a minimally invasive procedure, the implant uses a precision silicon nanofluidic membrane to maintain plasma levels above the threshold required for efficacy. Because the platform is long-acting and refillable, it is designed to support uninterrupted protection over time.
the nanoDDI
Encouraging preclinical evidence
Together, these findings suggest that nanofluidic implant-based delivery may support durable HIV prevention while reducing the burden of daily oral therapy.
Why HIV prevention still needs better delivery
Pre-exposure prophylaxis (PrEP) is highly effective, but its protection depends on consistency. For many people, taking a daily pill over months or years can be difficult to sustain. Missed doses may reduce protection, while treatment fatigue, anxiety, and cumulative drug exposure can add to the burden over time.
Long-acting delivery creates the potential to reduce that burden by shifting HIV prevention away from daily adherence and toward more consistent exposure over time.
A new era in long-acting prevention
Our nanoDDI represents more than an alternative to daily oral PrEP. By combining long duration, lower drug exposure, and refillability, it points toward a new model for HIV prevention, one designed to reduce daily burden while supporting more consistent protection over time.
